

Pre- and Post-Antibiotic Epoch: Rethinking Antimicrobial Resistance

Aiko Misaki Tanaka*

Kyoto University, Yoshida-honmachi, Sakyo-ku, Kyoto 606-8501, Japan

*: All correspondence should be sent to: Dr. Aiko Misaki Tanaka

Author's Contact: Dr. Aiko Misaki Tanaka, PhD, E-mail: aiko.tanaka@kyoto-u.ac.jp

DOI: <https://doi.org/10.15354/si.26.op105>

Funding: No funding source declared.

COI: The author declares no competing interest.

AI Declaration: The author affirms that artificial intelligence did not contribute to the process of preparing the work.

The global escalation of antimicrobial resistance (AMR) has transformed medicine into a precarious endeavor, challenging the foundational trust in antibiotics that has defined modern healthcare. The pre-antibiotic epoch was characterized by high morbidity and mortality from infections, where even minor injuries could become lethal. The post-antibiotic epoch, paradoxically, is emerging not from the absence of antibiotics but from their misuse, overprescription, and the consequent selection pressure that drives resistant pathogens. This transitional era compels a reevaluation of how societies, healthcare systems, and scientific research address infectious diseases. While antibiotic discovery slowed decades ago, resistance mechanisms proliferated, creating a silent but potent threat. Rethinking AMR requires more than novel drug development—it demands a paradigm shift in stewardship, diagnostics, public awareness, and global cooperation. This article argues that acknowledging the lessons of the pre-antibiotic era, understanding the vulnerabilities of our post-antibiotic present, and proactively reshaping clinical and societal behaviors are essential to preserving effective antimicrobial therapy for future generations.

Keywords: Antimicrobial Resistance; Antibiotics; Stewardship; Pre-Antibiotic Era; Post-Antibiotic Era

Science Insights, January 30, 2026; Vol. 48, No. 1, pp.2099-2102.

© 2026 Insights Publisher. All rights reserved.



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the [Creative Commons Attribution-NonCommercial 4.0 License](https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed by the Insights Publisher.

THE DISCOVERY OF ANTIBIOTICS is often heralded as one of the greatest achievements of modern medicine. Alexander Fleming's penicillin revolutionized the treatment of bacterial infections, shifting the medical landscape from

a pre-antibiotic world of high morbidity and mortality to an era in which infections were largely controllable (Fleming, 1929). In the decades that followed, antibiotics became synonymous with medical progress, their efficacy fostering both public trust and a sense

of invincibility within healthcare. However, this reliance has nurtured complacency and, paradoxically, seeded the very crisis threatening modern medicine: antimicrobial resistance (AMR) (Davies & Davies, 2010). The pre-antibiotic epoch offers critical context for understanding the stakes of this emerging threat. Before antibiotics, infectious diseases claimed millions of lives, and simple wounds or routine surgeries carried substantial risk. Treatments were largely supportive, and survival often depended on the patient's innate immune defenses rather than pharmacologic interventions. The absence of effective antimicrobials shaped medical decision-making, public health policy, and societal attitudes toward disease.

In the post-antibiotic epoch, we confront an unsettling reality: the very tools that defined medical progress are increasingly undermined by the organisms they were designed to suppress (World Health Organization, 2014). AMR is not a theoretical concern—it is a tangible, accelerating phenomenon. Multidrug-resistant bacteria, including strains of *Escherichia coli*, *Klebsiella pneumoniae*, and *Staphylococcus aureus*, compromise the treatment of common infections and threaten the feasibility of routine procedures, from appendectomies to chemotherapy (Centers for Disease Control and Prevention, 2019). This epoch, unlike the pre-antibiotic era, is not a result of technological absence but of human behavior. Misuse and overuse of antibiotics in clinical, agricultural, and industrial contexts have created selective pressure that drives microbial evolution at a pace previously unseen. Resistant organisms flourish, while the discovery pipeline for new antimicrobials lags, leaving healthcare systems vulnerable. In essence, we are witnessing a return to a world where previously treatable infections once again carry grave consequences—but this time with the specter of global interconnectedness amplifying the stakes.

Addressing AMR demands a paradigm shift in how antibiotics are perceived, prescribed, and utilized (World Health Organization, 2020). Traditional approaches—focusing solely on drug discovery—are insufficient. Antibiotic stewardship, rigorous infection control, and the development of rapid, accurate diagnostics must become central pillars of healthcare strategy. Stewardship programs aim to optimize antibiotic use, ensuring that these powerful drugs are employed only when necessary and in appropriate doses. Beyond hospitals, public awareness campaigns are crucial (Holmes et al., 2016). Misconceptions surrounding antibiotics, such as their efficacy against viral infections or self-prescription practices, perpetuate misuse and accelerate resistance. Similarly, agriculture contributes significantly to the crisis; antibiotics used for growth promotion in livestock promote resistant strains that can transfer to humans. Holistic strategies integrating medical, societal, and environmental dimensions are therefore essential.

Rethinking AMR also involves drawing lessons from the pre-antibiotic epoch. During that era, non-pharmacologic strategies were central: sanitation, hygiene, quarantine, and vaccination played pivotal roles in reducing disease burden (Murray et al., 2022). Many of these principles remain relevant and urgently necessary today. Improving access to clean water, enhancing infection prevention measures, and strengthening public health infrastructures are low-tech interventions with high impact. They act as a buffer against the spread of resistant pathogens while

reducing overall infection rates, thereby decreasing antibiotic demand. By revaluing these foundational practices, modern medicine can mitigate the reliance on antimicrobial agents and limit the selective pressure that fuels resistance.

Another dimension demanding attention is the inequity of AMR's impact. While developed nations often possess robust healthcare systems capable of managing resistant infections, low- and middle-income countries face disproportionate burdens due to inadequate healthcare infrastructure, limited access to diagnostics, and insufficient stewardship programs (Laxminarayan et al., 2013). Global cooperation is critical; resistance knows no borders. Policies must encourage equitable access to effective antimicrobials, foster international surveillance networks, and incentivize responsible pharmaceutical practices. The post-antibiotic epoch is not merely a medical challenge but a geopolitical and ethical one, demanding collaborative solutions that transcend national interests.

The crisis of AMR also compels reflection on the cultural and psychological dimensions of antibiotic reliance. In the decades following the introduction of penicillin, antibiotics became cultural symbols of certainty and control over illness (O'Neill, 2016). This perception persists, fueling patient expectations and prescriber habits that favor immediate pharmacologic solutions (World Health Organization, 2023). Reorienting societal attitudes toward illness, risk, and medical intervention is a subtle but necessary component of combating AMR. By fostering an understanding that not all infections require antibiotics and that judicious restraint benefits both individual and public health, societies can align behavioral practices with long-term preservation of antimicrobial efficacy.

Research and innovation remain essential but must be strategically aligned with stewardship principles. Novel antimicrobial agents, alternative therapies such as bacteriophage therapy, and immunomodulatory strategies offer promise but are not panaceas (Prestinaci et al., 2015). Their development must occur alongside measures that reduce unnecessary antibiotic exposure, maintain microbial susceptibility, and extend the lifespan of existing drugs. Integrating behavioral, technological, and policy interventions creates a multifaceted defense capable of addressing AMR from multiple angles.

Ultimately, the pre- and post-antibiotic epochs serve as instructive bookends for a critical period in human health (Ventola, 2015). The pre-antibiotic era demonstrates the devastating consequences of lacking effective therapeutics, while the post-antibiotic era warns of the perils inherent in overconfidence and mismanagement of these same tools. Recognizing the continuity between these periods highlights the fragility of progress and underscores the imperative for proactive, systemic, and global strategies. AMR is not merely a biomedical problem—it is a societal challenge, a reflection of collective human behavior, and a test of our capacity to balance technological prowess with prudent stewardship.

In conclusion, the era of antibiotics, once considered the pinnacle of medical triumph, is confronting its limits. The rising tide of antimicrobial resistance threatens to undo decades of public health progress, returning us to a landscape reminiscent of the pre-antibiotic epoch, where common infections can again be deadly. Addressing this challenge requires a comprehensive

rethinking of how antibiotics are used, a recommitment to foundational public health principles, and a global, coordinated approach that integrates innovation, stewardship, and education. By learning from the past and confronting the realities of the present, humanity can navigate this transitional epoch and preserve the

life-saving potential of antibiotics for generations to come. The stakes are high, but the path forward is clear: responsible use, rigorous infection control, and a holistic understanding of AMR are essential to safeguard the legacy of antimicrobial therapy.



Received: September 21, 2025 | Revised: November 05, 2025 | Accepted: December 16, 2025

References

- Centers for Disease Control and Prevention. (2019). Antibiotic resistance threats in the United States, 2019. U.S. Department of Health and Human Services. Available at: <https://www.cdc.gov>
- Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. *Microbiology and Molecular Biology Reviews*, 74(3), 417–433. DOI: <https://doi.org/10.1128/MMBR.00016-10>
- Fleming, A. (1929). On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of *B. influenzae*. *British Journal of Experimental Pathology*, 10(3), 226–236.
- Holmes, A. H., Moore, L. S. P., Sundsfjord, A., Steinbakk, M., Regmi, S., Karkey, A., ... Piddock, L. J. V. (2016). Understanding the mechanisms and drivers of antimicrobial resistance. *The Lancet*, 387(10014), 176–187. DOI: [https://doi.org/10.1016/S0140-6736\(15\)00473-0](https://doi.org/10.1016/S0140-6736(15)00473-0)
- Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., ... Cars, O. (2013). Antibiotic resistance—the need for global solutions. *The Lancet Infectious Diseases*, 13(12), 1057–1098. DOI: [https://doi.org/10.1016/S1473-3099\(13\)70318-9](https://doi.org/10.1016/S1473-3099(13)70318-9)
- Murray, C. J. L., Ikuta, K. S., Sharrara, F., Swetschinski, L., Aguilar, G. R., Gray, A., ... Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet*, 399(10325), 629–655. DOI: [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
- O'Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance. Available at: <https://amr-review.org>
- Prestinaci, F., Pezzotti, P., & Pantosti, A. (2015). Antimicrobial resistance: A global multifaceted phenomenon. *Pathogens and Global Health*, 109(7), 309–318. DOI: <https://doi.org/10.1179/2047773215Y.0000000030>
- Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. *Pharmacy and Therapeutics*, 40(4), 277–283.
- World Health Organization. (2014). *Antimicrobial resistance: Global report on surveillance*. WHO Press.
- World Health Organization. (2020). *Global action plan on antimicrobial resistance*. Available at: <https://www.who.int>
- World Health Organization. (2023). *Antimicrobial resistance*. Available at: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>